RxSight Statistics
Total Valuation
RxSight has a market cap or net worth of $302.48 million. The enterprise value is $85.39 million.
Important Dates
The last earnings date was Wednesday, February 25, 2026, after market close.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RxSight has 41.27 million shares outstanding. The number of shares has increased by 5.10% in one year.
| Current Share Class | 41.27M |
| Shares Outstanding | 41.27M |
| Shares Change (YoY) | +5.10% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 5.35% |
| Owned by Institutions (%) | 84.05% |
| Float | 36.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.25 |
| Forward PS | 2.25 |
| PB Ratio | 1.10 |
| P/TBV Ratio | 1.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.95, with a Debt / Equity ratio of 0.04.
| Current Ratio | 10.95 |
| Quick Ratio | 9.58 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,536.37 |
Financial Efficiency
Return on equity (ROE) is -13.99% and return on invested capital (ROIC) is -81.26%.
| Return on Equity (ROE) | -13.99% |
| Return on Assets (ROA) | -9.56% |
| Return on Invested Capital (ROIC) | -81.26% |
| Return on Capital Employed (ROCE) | -16.88% |
| Weighted Average Cost of Capital (WACC) | 10.21% |
| Revenue Per Employee | $291,711 |
| Profits Per Employee | -$84,477 |
| Employee Count | 461 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.17 |
Taxes
In the past 12 months, RxSight has paid $66,000 in taxes.
| Income Tax | 66,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.88% in the last 52 weeks. The beta is 1.15, so RxSight's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | -71.88% |
| 50-Day Moving Average | 8.74 |
| 200-Day Moving Average | 9.82 |
| Relative Strength Index (RSI) | 36.40 |
| Average Volume (20 Days) | 804,050 |
Short Selling Information
The latest short interest is 5.53 million, so 13.40% of the outstanding shares have been sold short.
| Short Interest | 5.53M |
| Short Previous Month | 5.36M |
| Short % of Shares Out | 13.40% |
| Short % of Float | 14.98% |
| Short Ratio (days to cover) | 4.99 |
Income Statement
In the last 12 months, RxSight had revenue of $134.48 million and -$38.94 million in losses. Loss per share was -$0.95.
| Revenue | 134.48M |
| Gross Profit | 103.01M |
| Operating Income | -48.19M |
| Pretax Income | -38.88M |
| Net Income | -38.94M |
| EBITDA | -44.93M |
| EBIT | -48.19M |
| Loss Per Share | -$0.95 |
Full Income StatementBalance Sheet
The company has $228.13 million in cash and $11.04 million in debt, with a net cash position of $217.09 million or $5.26 per share.
| Cash & Cash Equivalents | 228.13M |
| Total Debt | 11.04M |
| Net Cash | 217.09M |
| Net Cash Per Share | $5.26 |
| Equity (Book Value) | 275.68M |
| Book Value Per Share | 6.68 |
| Working Capital | 261.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.51 million and capital expenditures -$3.83 million, giving a free cash flow of -$19.34 million.
| Operating Cash Flow | -15.51M |
| Capital Expenditures | -3.83M |
| Free Cash Flow | -19.34M |
| FCF Per Share | -$0.47 |
Full Cash Flow StatementMargins
Gross margin is 76.60%, with operating and profit margins of -35.84% and -28.96%.
| Gross Margin | 76.60% |
| Operating Margin | -35.84% |
| Pretax Margin | -28.91% |
| Profit Margin | -28.96% |
| EBITDA Margin | -33.41% |
| EBIT Margin | -35.84% |
| FCF Margin | n/a |
Dividends & Yields
RxSight does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.10% |
| Shareholder Yield | -5.10% |
| Earnings Yield | -12.87% |
| FCF Yield | -6.39% |
Analyst Forecast
The average price target for RxSight is $11.60, which is 58.25% higher than the current price. The consensus rating is "Hold".
| Price Target | $11.60 |
| Price Target Difference | 58.25% |
| Analyst Consensus | Hold |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RxSight has an Altman Z-Score of 8.53 and a Piotroski F-Score of 2.
| Altman Z-Score | 8.53 |
| Piotroski F-Score | 2 |
